Clinical Trial Update: Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias [Phase 1]

View source ↗

Summary

Phase 1 study of TH-302 (evofosfamide), a hypoxia-activated prodrug, in patients with advanced leukemias has been completed, with evaluation across multiple mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• High-risk Myelodysplastic Syndrome
• Myelofibrosis

Drugs mentioned

• TH-302 (evofosfamide)

Snippet

Sponsor: Threshold Pharmaceuticals | Conditions: Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED